A Review of the Treatment for Multiple Myeloma
A panel of experts lead by Dr. Keith Stewart, MB, ChB, discuss the current treatment landscape of multiple myeloma.
Tap into peer-to-peer dialogues covering different therapeutic areas in easy to digest videos, featuring managed care thought leaders.
August 02, 2019 –
Experts examine how real-world data can help address some of the practical, personal, and economic issues that arise during treatment for multiple myeloma.
August 02, 2019 –
A review of the dosing strategies based on data from the ARROW study, for relapsed or refractory multiple myeloma.
July 26, 2019 –
Examining how daratumumab and other monoclonal antibodies will enhance results in the frontline treatment of multiple myeloma.
July 26, 2019 –
Experts discuss clinical implications and the significance of minimal residual disease (MRD) testing in patients with multiple myeloma.
July 19, 2019 –
Experts discuss the practical implications of the MAIA study for patients with newly diagnosed transplant-ineligible multiple myeloma.
July 19, 2019 –
Discussion on the personal approaches toward treatment for patients with relapsed or refractory multiple myeloma.
July 19, 2019 –
Experts review the economic factors that play into the high costs of treatment and care for patients with multiple myeloma.
July 19, 2019 –
Experts discuss how neuropathy plays a part in the treatment decisions for therapy in patients with multiple myeloma, who are ineligible for transplant.
July 12, 2019 –
Recommendations for the treatment of newly diagnosed multiple myeloma based on the National Comprehensive Cancer Network guidelines.
July 12, 2019 –
A review of the practical and clinical impact of maintenance therapy for patients with multiple myeloma.
